Valuation : Halozyme Therapeutics, Inc.

Market Cap 12.51B 10.76B 10.13B 9.25B 17.3B 1,181B 17.35B 120B 46.43B 606B 46.96B 45.94B 1,952B P/E 2026 *
15.3x
P/E 2027 * 12.3x
Enterprise Value 13.85B 11.92B 11.21B 10.24B 19.16B 1,308B 19.21B 133B 51.42B 671B 52.01B 50.87B 2,161B EV / Sales 2026 *
7.47x
EV / Sales 2027 * 6.25x
Free-Float
98.89%
Yield 2026 *
-
Yield 2027 * -
1 day-0.51%
1 week+4.59%
Current month+3.47%
1 month+28.49%
3 months+54.05%
6 months+63.56%
Current year+63.73%
1 week 105.48
Extreme 105.48
111.15
1 month 98.13
Extreme 98.13
111.15
Current year 61.32
Extreme 61.325
111.15
1 year 61.22
Extreme 61.225
111.15
3 years 32.83
Extreme 32.83
111.15
5 years 29.85
Extreme 29.85
111.15
10 years 8.18
Extreme 8.18
111.15
Manager TitleAgeSince
Chief Executive Officer 63 2014-01-05
Director of Finance/CFO 61 2013-04-30
Director of Finance/CFO - 2026-06-07
Director TitleAgeSince
Director/Board Member 59 2013-03-27
Director/Board Member 63 2014-01-05
Chairman 61 -
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Free

Director

2,939 0.0026%
8/19/26 Exercice

Chief Executive Officer

60,000 0.0506%
8/10/26 Sell

Director

-1,626 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%+4.59%+47.06%+168.63% 12.51B
-1.32%+1.33%+77.46%+41.17% 371B
-0.94%-3.38%+21.05%-19.80% 68.64B
-0.56%-9.06%-8.11%-8.78% 8.06B
+0.23%-1.59%-20.70%+6.13% 5.04B
0.00%-4.12%-31.60%+20.55% 4.51B
-0.35%-3.11%-33.77%+1.20% 3.07B
-1.00%-0.46%-5.37%+37.45% 2.53B
-0.50%-3.98%-24.35%-16.61% 2B
+0.12%-1.96%-25.07%-13.89% 1.7B
Average -0.49%-1.60%-0.34%+21.60% 47.89B
Weighted average by Cap. -1.20%+0.47%+63.15%+33.64%

Financials

2026 *2027 *
Net sales 1.85B 1.6B 1.5B 1.37B 2.56B 175B 2.57B 17.73B 6.88B 89.8B 6.96B 6.81B 289B 2.05B 1.76B 1.66B 1.52B 2.84B 194B 2.84B 19.62B 7.61B 99.34B 7.7B 7.53B 320B
Net income 869M 748M 703M 643M 1.2B 82.02B 1.21B 8.31B 3.23B 42.08B 3.26B 3.19B 136B 1.07B 919M 865M 790M 1.48B 101B 1.48B 10.22B 3.96B 51.73B 4.01B 3.92B 167B
Net Debt 1.34B 1.16B 1.09B 994M 1.86B 127B 1.86B 12.86B 4.99B 65.1B 5.05B 4.94B 210B 320M 275M 259M 236M 442M 30.17B 443M 3.06B 1.19B 15.48B 1.2B 1.17B 49.86B
Logo Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Employees
423
Date Price Change Volume
26-09-04 US$110.19 -0.51% 1,010,602
26-09-03 US$110.76 +1.00% 1,889,664
26-09-02 US$109.66 +1.80% 1,619,587
26-09-01 US$107.72 +1.16% 1,058,736
26-08-31 US$106.49 +1.08% 1,280,007
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
110.19USD
Average target price
99.56USD
Spread / Average Target
-9.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HALO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!